Perrine Devos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Perrine Devos has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Procureur
Sorbonne University, APHP, INSERM, CIC-1901, Hopital Pitié-Salpétrière, 75013 Paris, France
78 shared publications - Alban Redheuil
Sorbonne University, Department of Cardiovascular and Thoracic Radiology, Hôpital de la Pitié-Salpêtrière (AP-HP), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; Sorbonne University, Biomedical Imaging Laboratory (LIB), INSERM, CNRS, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
78 shared publications - Alexandre Demoule
INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France
78 shared publications - Aude Rigolet
12Sorbonne Université, INSERM, Department of Internal Medicine, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
78 shared publications - Baptiste Abbar
Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Institut national de la santé et de la recherche médicale (INSERM), Sorbonne University, Paris, France; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, Sorbonne University, Paris, France
78 shared publications - Capucine Morelot-Panzini
Department of Pneumology, département R3S, Hôpital Pitié-Salpêtrière, Assistance Publique—Hôpitaux de Paris, Sorbonne Université , Paris
78 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Examples of cardiac and skeletal muscle pathology findings on autopsies of 2 patients
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Examples of cardiac and skeletal muscle pathology findings on autopsies of 2 patients
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Treatment modalities and reported adverse events by quartile of period of inclusion.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Treatment modalities and reported adverse events by quartile of period of inclusion.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Methods concerning Immune-checkpoint proteins profiling on peripheral blood mononuclear cells and Circulating immune checkpoint agents drug monitoring
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Methods concerning Immune-checkpoint proteins profiling on peripheral blood mononuclear cells and Circulating immune checkpoint agents drug monitoring
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Proposed management algorithm for ICI-myotoxicities as a function of severity criteria grading
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Proposed management algorithm for ICI-myotoxicities as a function of severity criteria grading
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Delay between presentation for ICI myocarditis, appearance of life-threatening myotoxicity criteria (severity grade 4, Supplementary Table 5 for details concerning grading) and start of the immunosuppressive treatments (with dose) in severe ICI-myocarditis patients requiring abatacept.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Delay between presentation for ICI myocarditis, appearance of life-threatening myotoxicity criteria (severity grade 4, Supplementary Table 5 for details concerning grading) and start of the immunosuppressive treatments (with dose) in severe ICI-myocarditis patients requiring abatacept.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Example of the first severe ICI-myocarditis case treated with abatacept guided by real-time immune-monitoring assessment of CD86RO (CD86 receptor occupancy) on circulating monocytes.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Example of the first severe ICI-myocarditis case treated with abatacept guided by real-time immune-monitoring assessment of CD86RO (CD86 receptor occupancy) on circulating monocytes.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Diagnostic certainty criteria for ICI-myocarditis
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Diagnostic certainty criteria for ICI-myocarditis
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Diagnostic work-up for suspected ICI-myocarditis and evaluation of severity criteria
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Diagnostic work-up for suspected ICI-myocarditis and evaluation of severity criteria
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Definitions used for adjudication and grading of the different evaluated events
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Definitions used for adjudication and grading of the different evaluated events
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Effect of plasmapheresis on ICI circulating levels in the 10 patients receiving plasmapheresis in our cohort.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Effect of plasmapheresis on ICI circulating levels in the 10 patients receiving plasmapheresis in our cohort.